Filing Flows › Quanterix (QTRX) › Guidance & outlook
Quanterix (QTRX) guidance and outlook
Quanterix (QTRX) lowered its guidance on Nov 9, 2026: Revenue $142M–$146M for FY2026; Gross margin 48%–50% for FY2026. Quanterix's 10-Q filed Nov 9, 2026 makes 16 forward-looking statements.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $142M–$146M | lowered |
| Gross margin | FY2026 | 48%–50% | reaffirmed |
From the earnings release filed Nov 9, 2026 (8-K on EDGAR).
Forward-looking statements, 10-Q filed Nov 9, 2026
- We believe the combination of our SIMOA and spatial technologies will enable scientists to drive diagnostic innovation in the evolving healthcare landscape with data across the tissue to fluid continuum.
- As the installed base of our instruments increases, we expect total consumables revenue to increase.
- To date, we have completed over 2,650 projects for more than 500 customers throughout the world using our platforms.
- We expect operating losses to continue into 2027 as we incur costs related to the following:
- Upon completion of the review, in May 2026 and August 2026 we announced several significant changes intended to accelerate revenue growth in our research tools business and to further advance our position in the Alzheimer’s disease diagnostics market.
- These investments are intended to strengthen sales execution and competitive positioning and deepen our pharmaceutical partnerships.
- We believe these initiatives began to positively impact our revenues in the third quarter of 2026 and we expect this trend to increase into 2027.
- We expect softness in instrument sales to continue into 2027 as a result of what we believe is a constrained capital funding environment.
- We continue to see strong opportunities in the market and believe the strategic changes we made to our commercial organization will drive an increase in Accelerator Laboratory revenue into 2027.
- We believe that our continued investment in research and development is essential to our long-term competitive position and we expect to maintain research and development expense at a more consistent level period to period in the future.
- We do not expect selling, general and administrative expenses in future periods to change at the same rate as total revenue or research and development expenses.
- Our liquidity requirements have consisted, and we expect that they will continue to consist, of sales and marketing expenses, research and development expenses, working capital, general corporate expenses, and contingent payments related to our prior acquisition activity.
Quanterix's latest quarter
Quanterix, Q3 2026: revenue $35.0M (-13% year over year), operating margin -64.3%, net loss $21.6M, operating cash flow −$16.2M. The chart follows the revenue to costs, profit and cash.
Questions
Did Quanterix raise or lower its guidance?
Quanterix (QTRX) lowered its guidance on Nov 9, 2026: Revenue $142M–$146M for FY2026; Gross margin 48%–50% for FY2026.
What does Quanterix expect?
We believe the combination of our SIMOA and spatial technologies will enable scientists to drive diagnostic innovation in the evolving healthcare landscape with data across the tissue to fluid continuum. As the installed base of our instruments increases, we expect total consumables revenue to increase. To date, we have completed over 2,650 projects for more than 500 customers throughout the world using our platforms.
Updated Nov 9, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.